Table 3

Factors associated with death in survival analysis

VariableHR (95% CI)P*aHR (95% CI)P*
Molecular diagnosis (ARTEMIS) 0.9 (0.7-1.0) .07   
Viral infection prior to transplantation 2.9 (2.1-4.0) <.0001 3.1 (2.2-4.3) <.0001 
Age in mo at diagnosis (≥3 mo) 1.8 (1.4-2.4) <.0001 1.5 (1.1-1.9) .003 
Myeloablative conditioning 1.5 (1.0-2.3) .05   
Donor identity  .003   
 MSD    
 MFD 0.9 (0.3-2.6) .8   
 MMFD 5.4 (1.9-15.4) .001   
 Haploidentical 4.5 (1.0-20.9) .06   
 MUD 3.6 (2.4-5.3) <.0001   
Retransplantation 2.5 (1.5-4.1) .001 2.2 (1.4-3.4) .001 
Additional procedure (re-HCT, boost) 1.6 (1.2-2.2) .003   
Early infection (≤2 y post-HCT) 1.9 (1.0-3.7) .04   
Chronic GVHD (≤2 y post-HCT) 1.5 (1.2-1.7) <.0001 1.3 (1.2-1.5) <.0001 
VariableHR (95% CI)P*aHR (95% CI)P*
Molecular diagnosis (ARTEMIS) 0.9 (0.7-1.0) .07   
Viral infection prior to transplantation 2.9 (2.1-4.0) <.0001 3.1 (2.2-4.3) <.0001 
Age in mo at diagnosis (≥3 mo) 1.8 (1.4-2.4) <.0001 1.5 (1.1-1.9) .003 
Myeloablative conditioning 1.5 (1.0-2.3) .05   
Donor identity  .003   
 MSD    
 MFD 0.9 (0.3-2.6) .8   
 MMFD 5.4 (1.9-15.4) .001   
 Haploidentical 4.5 (1.0-20.9) .06   
 MUD 3.6 (2.4-5.3) <.0001   
Retransplantation 2.5 (1.5-4.1) .001 2.2 (1.4-3.4) .001 
Additional procedure (re-HCT, boost) 1.6 (1.2-2.2) .003   
Early infection (≤2 y post-HCT) 1.9 (1.0-3.7) .04   
Chronic GVHD (≤2 y post-HCT) 1.5 (1.2-1.7) <.0001 1.3 (1.2-1.5) <.0001 

Only significant results in univariate analysis are shown. The hazard proportionality assumption was verified for all variables. Patients were clustered using a group variable to take into account the practice variations between centers.

aHR, adjusted hazard ratio; HR, hazard ratio; MFD, matched family donor; MMFD, mismatched family donor; MSD, matched sibling donor; MUD, matched unrelated donor.

*

P values are referring to univariate analysis (left column) and multivariate analysis (right column), respectively.

or Create an Account

Close Modal
Close Modal